These data indicate that anti-VEGF treatment significantly enhances the efficacy of PD-L1 inhibition and a combination of PD-L1 and VEGF blockade is likely required to augment anticancer immunity in patients with unresectable HCC. Here, VEGFA is linked to hepatocellular carcinoma.